Cmax of interest? [Regulatives / Guidelines]

posted by Dr_Dan  – Germany, 2011-10-10 18:57 (5376 d 00:01 ago) – Posting: # 7461
Views: 5,079

Dear Helmut
Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of H+/K+-ATPase in the gastric parietal cell. By acting specifically on the proton pump, esomeprazole blocks the final step in acid production, thus reducing gastric acidity. This effect is dose-related. Therefore the bioavalability in terms of total exposure (AUC) controls the effect and is consequently of much more interest than bioavailability in terms of peak exposure (tmax and Cmax). This is what the assessor had in mind (I guess). Therefore widening of acceptance range was clinically justified.
But I agree, seen under formal aspects the widening of the acceptance range should have been not possible at that time.
Kind regards
Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
214 visitors (0 registered, 214 guests [including 15 identified bots]).
Forum time: 18:59 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5